Acurx Pharmaceuticals (ACXP) Competitors $1.39 -0.28 (-16.77%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends ACXP vs. INDP, AGRX, MNOV, GBIO, MIST, ORMP, ADAG, IVVD, SLS, and ASRTShould you be buying Acurx Pharmaceuticals stock or one of its competitors? The main competitors of Acurx Pharmaceuticals include Indaptus Therapeutics (INDP), Agile Therapeutics (AGRX), MediciNova (MNOV), Generation Bio (GBIO), Milestone Pharmaceuticals (MIST), Oramed Pharmaceuticals (ORMP), Adagene (ADAG), Invivyd (IVVD), SELLAS Life Sciences Group (SLS), and Assertio (ASRT). These companies are all part of the "pharmaceutical products" industry. Acurx Pharmaceuticals vs. Indaptus Therapeutics Agile Therapeutics MediciNova Generation Bio Milestone Pharmaceuticals Oramed Pharmaceuticals Adagene Invivyd SELLAS Life Sciences Group Assertio Indaptus Therapeutics (NASDAQ:INDP) and Acurx Pharmaceuticals (NASDAQ:ACXP) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, media sentiment, risk, valuation, community ranking, dividends and earnings. Do analysts prefer INDP or ACXP? Indaptus Therapeutics currently has a consensus target price of $8.50, suggesting a potential upside of 694.39%. Acurx Pharmaceuticals has a consensus target price of $12.00, suggesting a potential upside of 763.31%. Given Acurx Pharmaceuticals' higher possible upside, analysts plainly believe Acurx Pharmaceuticals is more favorable than Indaptus Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Indaptus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Acurx Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has higher valuation & earnings, INDP or ACXP? Acurx Pharmaceuticals is trading at a lower price-to-earnings ratio than Indaptus Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIndaptus TherapeuticsN/AN/A-$15.42M-$1.71-0.63Acurx PharmaceuticalsN/AN/A-$14.58M-$1.09-1.28 Is INDP or ACXP more profitable? Indaptus Therapeutics' return on equity of -177.27% beat Acurx Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Indaptus TherapeuticsN/A -177.27% -141.06% Acurx Pharmaceuticals N/A -392.36%-223.78% Which has more risk & volatility, INDP or ACXP? Indaptus Therapeutics has a beta of 1.45, meaning that its stock price is 45% more volatile than the S&P 500. Comparatively, Acurx Pharmaceuticals has a beta of -1.73, meaning that its stock price is 273% less volatile than the S&P 500. Does the media favor INDP or ACXP? In the previous week, Acurx Pharmaceuticals had 17 more articles in the media than Indaptus Therapeutics. MarketBeat recorded 18 mentions for Acurx Pharmaceuticals and 1 mentions for Indaptus Therapeutics. Acurx Pharmaceuticals' average media sentiment score of 0.61 beat Indaptus Therapeutics' score of 0.28 indicating that Acurx Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Indaptus Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Acurx Pharmaceuticals 2 Very Positive mention(s) 3 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders hold more shares of INDP or ACXP? 7.1% of Indaptus Therapeutics shares are held by institutional investors. Comparatively, 11.5% of Acurx Pharmaceuticals shares are held by institutional investors. 29.5% of Indaptus Therapeutics shares are held by company insiders. Comparatively, 29.6% of Acurx Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Does the MarketBeat Community prefer INDP or ACXP? Indaptus Therapeutics and Acurx Pharmaceuticals both received 13 outperform votes by MarketBeat users. However, 92.86% of users gave Acurx Pharmaceuticals an outperform vote while only 86.67% of users gave Indaptus Therapeutics an outperform vote. CompanyUnderperformOutperformIndaptus TherapeuticsOutperform Votes1386.67% Underperform Votes213.33%Acurx PharmaceuticalsOutperform Votes1392.86% Underperform Votes17.14% SummaryAcurx Pharmaceuticals beats Indaptus Therapeutics on 8 of the 13 factors compared between the two stocks. Ad Angel PublishingTesla Execs are Freaking OutIt’s so revolutionary that tech giants like Microsoft, Amazon, and NVIDIA are all lining up to get their hands on it. And Elon Musk has completely restructured Tesla to chase this opportunity. This is a once-in-a-lifetime opportunity that you don’t want to miss.Click here to get the details. Get Acurx Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ACXP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACXP vs. The Competition Export to ExcelMetricAcurx PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$23.48M$6.48B$5.05B$8.87BDividend YieldN/A8.12%4.97%4.06%P/E Ratio-1.285.5697.3414.18Price / SalesN/A348.141,218.4289.42Price / CashN/A22.1533.5132.79Price / Book4.097.885.805.12Net Income-$14.58M$153.61M$119.07M$225.99M7 Day Performance-21.47%-2.00%-1.83%-1.32%1 Month Performance-29.08%-7.47%-3.64%0.60%1 Year Performance-62.63%31.80%31.62%26.23% Acurx Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACXPAcurx Pharmaceuticals2.3812 of 5 stars$1.39-16.8%$12.00+763.3%-61.6%$23.48MN/A-1.283Short Interest ↓Analyst RevisionNews CoverageGap UpHigh Trading VolumeINDPIndaptus Therapeutics3.0922 of 5 stars$1.07+3.9%$8.50+694.4%-48.7%$10.50MN/A0.006AGRXAgile Therapeutics0.132 of 5 stars$1.51flatN/A-28.8%$10.35M$19.98M-0.4130MNOVMediciNova0.668 of 5 stars$1.95+2.6%N/A-5.3%$93.19M$1M0.0010News CoverageGap UpGBIOGeneration Bio3.359 of 5 stars$1.35-2.9%$7.50+455.6%+7.1%$92.84M$5.90M0.00150MISTMilestone Pharmaceuticals2.6273 of 5 stars$1.86+6.9%$12.00+545.2%-18.4%$92.79M$1M0.0030ORMPOramed Pharmaceuticals1.4846 of 5 stars$2.26-1.7%N/A+4.6%$92.72M$1.34M4.4310News CoverageADAGAdagene2.974 of 5 stars$2.09-5.9%$5.00+139.2%+52.6%$92.53M$815,746.000.00260News CoveragePositive NewsGap UpIVVDInvivyd2.5274 of 5 stars$0.77flat$7.52+878.6%-48.8%$91.88M$11.56M-0.39100Analyst ForecastSLSSELLAS Life Sciences Group1.424 of 5 stars$1.24-3.9%$3.00+141.9%+26.3%$90.79M$1M0.0016Gap UpASRTAssertio3.1511 of 5 stars$0.95-2.1%$3.25+242.1%-23.4%$90.71M$152.07M-1.3020 Related Companies and Tools Related Companies Indaptus Therapeutics Alternatives Agile Therapeutics Alternatives MediciNova Alternatives Generation Bio Alternatives Milestone Pharmaceuticals Alternatives Oramed Pharmaceuticals Alternatives Adagene Alternatives Invivyd Alternatives SELLAS Life Sciences Group Alternatives Assertio Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ACXP) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acurx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acurx Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
